Hims & Hers' (NYSE: HIMS) stock crashed over 30% following news highlighting the end of its relationship with Novo Nordisk ...

Regional bank Provident Financial Services (NYSE:PFS) rose by 5.8% on Thursday after Raymond James initiated coverage on the ...

Hims & Hers Health, Inc. (NYSE:HIMS) is one of the 10 Stocks Delivering Eye-Popping Gains. Hims & Hers rebounded by 11.76 ...

Novo Nordisk ends partnership with Hims & Hers, causing a 35% plunge. With no near-term catalysts, learn why investors must ...

Gain 2x leveraged exposure to HIMS with HIMZ, ideal for high-risk traders. Read more on how to navigate recent volatility and ...

Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.

This growth stock experienced a significant decline in stock price following an announcement with a key partner. *Stock prices used were the afternoon prices of June 23, 2025. The video was published ...

Wegovy (semaglutide) will no longer be available through Hims & Hers Health, as Novo Nordisk has ended its short-lived partnership.

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

Novo Nordisk is expanding access to its drug Wegovy through a new partnership with WeightWatchers, days after cutting ties with telehealth firm Hims & Hers. Starting July 1, WeightWatchers will ...

Novo Nordisk end their partnership with Hims & Hers; update to Vizamyl labeling; autoinjector approved for pediatrics with lupus nephritis; psilocybin shows promise in treatment-resistant depression; ...